HBC

Hereditary Breast Cancer

Hereditary Breast Cancer

All breast cancers are due to mutations ( changes ) in the genes. If these changes (mutations) are acquired at the time of birth from the parents, then that cancer is called Hereditary Breast Cancer. These are relatively small in number and the majority of the breast cancers are due to mutations acquired after birth. They could be because of the lifestyle, pollution, age and so on.

Hereditary breast cancer accounts for approximately 5–10% of all breast cancer cases. Identifying hereditary breast cancer is essential for tailoring prevention, screening, and treatment strategies for affected individuals and their families.

Some of the common genes know to be hereditable are BRCA 1, 2, PAL B2, PTEN, TP53, CHEK2 & CDH1.

Key Characteristics of Hereditary Breast Cancer

Early Onset

Often diagnosed at a younger age
(before 50 years).

Family History

Multiple relatives with breast, ovarian, or other associated cancers.

Bilateral Cancers

Higher likelihood of bilateral breast cancer or multiple primary cancers.

Rare Cancer Types

Includes male breast cancer, medullary breast cancer, or other specific subtypes.

Associated Cancers

Linked to ovarian, pancreatic, prostate, and other cancers depending on the mutation.

Hereditary Breast Cancer is not more aggressive than other breast cancer and hence these patients will have outcomes similar to others. They are suitable for breast conservation surgeries like regular breast cancer patients.

Implications of Positive result of Gene testing in a Diagnosed Breast Cancer Patient.

Before Initiation of Treatment

After Completion of Treatment

Implications of Gene Positivity in a lady without Breast Cancer is to institute regular Screening to Prevent development of Hereditary Breast Cancer

1. Enhanced Screening

2. Risk-Reducing Strategies

  • Risk-reducing mastectomy can lower breast cancer risk by 90–95%.
  • Salpingo-oophorectomy (removal of ovaries and fallopian tubes) reduces ovarian cancer risk and may lower breast cancer risk in premenopausal women.
  • Use of tamoxifen or raloxifene for hormone receptor-positive breast cancer risk reduction.